|
A research group from a Spanish university has developed new rifamycin derivatives from the spiropiperidylrifamycins family and a procedure for their preparation. These new compounds exhibit a high antibiotic activity and therefore can be used for the treatment of mycobacterial infections such as multi-resistant tuberculosis. Collaboration is sought for commercial exploitation of this technology via license agreement.
Multi-resistant tuberculosis is defined as that
tuberculosis which is caused by starins of Mycobacterium tuberculosis resistant simultaneously to at
least isoniazid and rifampicin. Its incidence has increased in the last years in an alarming rate in
numerous regions worldwide. The importance of this problem is illustrated in the decision taken by
the WHO (World Health Organization) in 1994 to put into action a plan for the control and
surveillance of multiresistant tuberculosis at a worldwide level. Among the strategies that have
been developed against this serious problem which threatens worldwide health, is the development of
new drugs to fight the types of strains involved.
The Spanish university has developed and patented
new rifamycin derivatives from the spiropiperidylrifamycins family, which exhibit a high antibiotic
activity, and also a procedure for their preparation.
The formula of the compound is shown in the
attached image, wherein R1 is a radical selected between hydrogen and alkyl; R2 is selected from
hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in position 3 and 4; R3 is
selected from phenyl, phenyl mono-substituted and phenyl di-substituted in position 3 and 4; the
substituents of the of the phenyl of R2 and R3 selected from halogen, (C1-C4)-alkyl and
(C1-C4)-alkoxyl and R4 is selected from hydrogen, alkyl, allyl and homoallyl.
The above described
compound, with their pharmaceutically acceptable salts and their solvates, have proved to be useful
for the treatment of mycobacterial infections, in particular for the treatment of infections
produced by Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex or Mycobacterium
kansasi.
Innovative Aspects:
The antimycobacterial activity of these new spiropiperidylrifamycins
are comparable and, in many cases better, than the one shown by the existing drugs at present time.
Domain of Application
Pharmaceutical and Medicinal application
Stage of Development
Development phase - Laboratory tested
Exploitation of RTD Results
National Programmes
IPR
Patent(s) applied for but not yet granted
European
Patent Applied: EP 1 783 129 A1
Company Details
Type: Research institute/University
Size: >
500
Collaboration Type
- Type of partner sought: industry.
- Specific area of activity of the partner: Pharmaceutical industry.
- Task to be performed by the partner sought: commercial exploitation of the patent.
|
